
Dyadic International DYAI
$ 0.94
-1.49%
Quarterly report 2025-Q3
added 11-12-2025
Dyadic International Accounts Payables 2011-2026 | DYAI
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Dyadic International
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 656 K | 1.28 M | 1.55 M | 1.01 M | 943 K | 309 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.55 M | 309 K | 958 K |
Quarterly Accounts Payables Dyadic International
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.21 M | 739 K | 482 K | 562 K | 433 K | 661 K | 656 K | 600 K | 906 K | 770 K | 1.28 M | 777 K | 1.1 M | 866 M | 1.55 M | 958 K | 2.43 M | 1.47 M | 1.01 M | 1.01 M | 1.01 M | 1.01 M | 943 K | 943 K | 943 K | 943 K | 309 K | 309 K | 309 K | 309 K | 520 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 866 M | 309 K | 28.8 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Adagene
ADAG
|
4.24 M | $ 1.65 | 7.91 % | $ 92.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
1.97 M | $ 1.52 | -16.3 % | $ 388 M | ||
|
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | ||
|
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | ||
|
Biogen
BIIB
|
424 M | $ 184.48 | -1.67 % | $ 26.9 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 4.25 | 1.67 % | $ 9.25 B | ||
|
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M | ||
|
Catalyst Biosciences
CBIO
|
355 K | $ 10.84 | 0.46 % | $ 714 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
8.13 M | - | -15.15 % | $ 60.3 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
15.4 M | $ 37.35 | -0.4 % | $ 3.86 B | ||
|
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
16.6 M | $ 23.18 | 2.02 % | $ 2.75 B | ||
|
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | ||
|
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | ||
|
Celldex Therapeutics
CLDX
|
3.26 M | $ 25.59 | -6.54 % | $ 1.65 M | ||
|
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M | ||
|
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
30.5 M | $ 29.43 | 6.09 % | $ 1.43 B | ||
|
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | ||
|
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | ||
|
Brickell Biotech
BBI
|
406 K | - | -5.38 % | $ 6.06 M | ||
|
Aravive
ARAV
|
8.76 M | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
13.3 M | - | -6.81 % | $ 3.04 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
17.7 M | $ 66.05 | 2.3 % | $ 8.83 B | ||
|
Athersys
ATHX
|
9.16 M | - | 3.77 % | $ 22.4 M | ||
|
Avenue Therapeutics
ATXI
|
155 K | - | -52.27 % | $ 4.45 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
5.85 M | $ 55.11 | 3.49 % | $ 4.45 B | ||
|
Abeona Therapeutics
ABEO
|
1.86 M | $ 5.14 | -1.06 % | $ 110 M | ||
|
CRISPR Therapeutics AG
CRSP
|
14.7 M | $ 55.17 | 2.47 % | $ 4.65 B | ||
|
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | ||
|
Axon Enterprise
AXON
|
72 M | $ 632.29 | 0.09 % | $ 47.9 B | ||
|
ADiTx Therapeutics
ADTX
|
10.2 M | $ 0.81 | 1.96 % | $ 10.7 K | ||
|
Aytu BioScience
AYTU
|
10.6 M | $ 2.7 | 2.27 % | $ 17 M |